RBC Capital on ADC Therapeutics (ADCT): 'We think the downside is unwarranted and would be buyers on weakness'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $5.00 price target on ADC Therapeutics (NYSE: ADCT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
